Data gathered: January 21
AI Stock Analysis - Gilead Sciences (GILD)
Analysis generated September 16, 2024. Powered by Chat GPT.
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines. The company's primary areas of focus include antiviral therapeutics, particularly in the fields of HIV, hepatitis B and C, and influenza. Gilead has a rich portfolio of products and an active pipeline of investigational drugs, positioning itself as a key player in the biopharma industry.
Stock Alerts - Gilead Sciences (GILD)
 |
Gilead Sciences | January 17 Insider Alert: Dickinson Andrew D is selling shares |
|
Gilead Sciences | December 30 Marjorie Taylor Greene (member of U.S. congress) is buying shares |
|
Gilead Sciences | December 24 Business Outlook among employees is up by 3.5% over the last month. |
|
Gilead Sciences | December 18 Insider Alert: Dickinson Andrew D is continuing selling shares |
Alternative Data for Gilead Sciences
About Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
| Price | $91.84 |
| Target Price | Sign up |
| Volume | 6,840,000 |
| Market Cap | $114B |
| Year Range | $61.59 - $97.09 |
| Dividend Yield | 3.35% |
| PE Ratio | 1020.44 |
| Analyst Rating | 62% buy |
| Earnings Date | February 11 '25 |
| Industry | Biotechnology |
In the news
 |
Merit Financial Group LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)January 21 - ETF Daily News |
|
Q2 EPS Estimates for Gilead Sciences Boosted by AnalystJanuary 20 - ETF Daily News |
|
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc.January 20 - ETF Daily News |
|
Park Avenue Securities LLC Buys 6,878 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)January 18 - ETF Daily News |
 |
Earnings Preview: What to Expect From Gilead Sciences’ ReportJanuary 17 - Biztoc.com |
|
Accurate Wealth Management LLC Has $311,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)January 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 7.54B | 4.79B | 2.76B | 1.25B | 1.88B | 2.020 |
| Q2 '24 | 6.98B | 2.94B | 4.04B | 1.61B | 2.98B | 2.010 |
| Q1 '24 | 6.46B | 5.42B | 1.04B | -4.17B | -3.54B | -1.320 |
| Q4 '23 | 6.87B | 5.08B | 1.79B | 1.43B | 2.52B | 1.720 |
| Q3 '23 | 6.82B | 3.48B | 3.34B | 2.18B | 3.16B | 2.290 |
Insider Transactions View All
| Dickinson Andrew D filed to sell 129,873 shares at $91.4. January 16 '25 |
| Dickinson Andrew D filed to sell 132,373 shares at $92. December 17 '24 |
| Dickinson Andrew D filed to sell 266,849 shares at $92.8. December 3 '24 |
| Dickinson Andrew D filed to sell 138,919 shares at $92.8. December 3 '24 |
| Parsey Merdad filed to sell 91,200 shares at $91.8. November 29 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Marjorie Taylor Greene |
Dec 30, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Jun 5, 24 | Buy | $1K - $15K |
| Thomas Tuberville Republican |
May 15, 24 | Buy | $1K - $15K |
Read more about Gilead Sciences (GILD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Gilead Sciences?
The Market Cap of Gilead Sciences is $114B.
What is Gilead Sciences' PE Ratio?
As of today, Gilead Sciences' PE (Price to Earnings) ratio is 1020.44.
When does Gilead Sciences report earnings?
Gilead Sciences will report its next earnings on February 11 '25.
What is the current stock price of Gilead Sciences?
Currently, the price of one share of Gilead Sciences stock is $91.84.
How can I analyze the GILD stock price chart for investment decisions?
The GILD stock price chart above provides a comprehensive visual representation of Gilead Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gilead Sciences shares. Our platform offers an up-to-date GILD stock price chart, along with technical data analysis and alternative data insights.
Does GILD offer dividends to its shareholders?
Yes, Gilead Sciences (GILD) offers dividends to its shareholders, with a dividend yield of 3.35%. This dividend yield represents Gilead Sciences' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Gilead Sciences in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Gilead Sciences?
Some of the similar stocks of Gilead Sciences are Amgen, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.